Akums Drugs & Pharmaceuticals Ltd

(AKUMS)

Akums Drugs Hits Upper Circuit After Major Agreement - 22 Nov, 2024

Akums Drugs & Pharmaceuticals shares reached the 5% upper circuit limit at ₹640.10 following an exclusive Master Sales Agreement with Caregen Co. Ltd. This agreement grants Akums exclusive rights to sell certain Caregen products in India, enhancing its market position in the Nutraceuticals segment.

Akums Drugs Hits New High Amid Sales Agreement - 21 Nov, 2024

Akums Drugs shares reached a new high, hitting a 5% upper circuit after signing a sales agreement with Caregen. Despite a challenging Q2FY25 with declining revenue and Ebitda, profit after tax rose 9% year-on-year. The management noted sequential growth across key financial metrics.

Akums Drugs Gains 5% on Caregen Agreement - 19 Nov, 2024

Akums Drugs & Pharmaceuticals shares rose 5% following an exclusive Master Sales Agreement with South Korea's Caregen, granting rights to market nutraceutical products in India. Despite recent revenue declines, the partnership is expected to enhance market presence.

Akums Drugs Faces Decline Amid Weak Earnings Outlook - 14 Nov, 2024

Akums Drugs and Pharmaceuticals shares dropped 5% following a weak Q2 earnings report, projecting flat revenue growth for FY25. The stock has declined significantly, falling below its IPO price due to concerns over revenue and margin stability in its CDMO business.

Akums Drugs Faces Significant Share Price Decline - 13 Nov, 2024

Akums Drugs' share price hit a lower circuit of 5% at ₹612.7, marking a 23% decline this week. Q2FY25 earnings showed a 28% YoY EBITDA drop and a 12.5% revenue decrease, indicating weak operational performance amid competitive pressures.

Akums Drugs Faces Revenue Decline Amid Profit Growth - 12 Nov, 2024

Akums Drugs & Pharmaceuticals reported a 16% rise in net profit despite an 11.9% revenue decline. Shares fell significantly following weak Q2 results, reaching a 52-week low. The company anticipates flat revenues for 2024-25 while focusing on maintaining margins in its CDMO business.

Akums Drugs Shares Fall Despite Strong Profit Growth - 11 Nov, 2024

Akums Drugs' stock fell over 4% following mixed Q2 FY25 results. Revenue dropped 12.5% YoY to ₹1,033.09 crore, but net profit surged 103.8% YoY to ₹66.65 crore.